Model‐based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer

Ejemplares similares

• Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus
  por: Junyi Wu, et al.
  Publicado: (2024)
• A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects
  por: Yusuke Tadayasu, et al.
  Publicado: (2024)
• Improving cefazolin exposure in critically ill children using a population pharmacokinetic model
  por: Clémence Rivaud, et al.
  Publicado: (2024)
• Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study
  por: Hiromitsu Imai, et al.
  Publicado: (2024)
• Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study
  por: Xiaoying Zhao, et al.
  Publicado: (2025)